Global Myasthenia Gravis Market Growth, Drivers & Market Opportunities till 2025

Posted on 2018-02-20 by Mark Hub in Healthcare, Pharmaceuticals // 0 Comments

Albany, USA, 2018-Feb-20 — /EPR Network/ —An up-to-date research report has been disclosed by Market Research Reports Search Engine highlighting the title “Myasthenia Gravis Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” which provides an outlook of current market value as well as the expected forecast including Rate on Investment (ROI) together with growing CAGR of XX% during 2018-2025. The report studies the medical oxygen equipment market worldwide, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, size, growth, revenue, consumption, import and export in these regions.

Click here For Free Sample Report @ https://www.mrrse.com/sample/4094

The global myasthenia gravis market is treading a growth path owing to the need to prevent deterioration of quality of life due to myasthenia gravis. Myasthenia gravis is an autoimmune disorder and neuromuscular disorder that causes weakness of muscles. The condition is characterized by fatigue and weakness of skeletal muscles. Muscles that monitor swallowing and breathing, eye movement, eye lids, and shoulder and facial muscles are the ones that are usually impacted in myasthenia gravis.

The growth of myasthenia gravis market is also driven by research and development initiatives for novel therapeutics. Key players in the market are also engaged in research to launch affordable therapeutics for myasthenia gravis.

A report by Market Research Reports Search Engine (MRRSE) projects the global myasthenia gravis market to become worth US$2,313.1 mn by 2025 from US$975.1 mn in 2016 at a CAGR of 10.1% therein.

Rising Acceptance of Robotic-assisted Therapeutics to Benefit Thymectomy Treatment Segment

The report studies the global myasthenia gravis market on the basis of treatment and geography. The key treatment segments include drug treatment, rapid immunotherapies, and thymectomy. The drug treatment segment is sub-segmented into cholinesterase inhibitors, monoclonal antibodies, and chronic Immunomodulators. The rapid immunotherapies segment is categorized into plasmapheresis and intravenous immunoglobulin. The cholinesterase inhibitors within drug treatment sub-segment blocks the breakdown of acetylcholine which acts as a neurotransmitter in both central and peripheral nervous system.

On the other hand, chronic immunomodulators within drug treatment segment are chemical agents which are responsible for modifying the immune response of the immune system by inhibition of white blood cell activity.

The plasmapheresis sub-segment within rapid immunotherapies segment involves removal, treatment, or exchange of blood plasma or components for myasthenia gravis. The duration of the treatment usually lasts from one to three hours. The removal of plasma provides relief from symptoms of muscle weakness. The process involves selective removal of patient’s plasma by means of specific intravenous fluids.

For More Info, Read Complete Report with TOC @ https://www.mrrse.com/myasthenia-gravis-market

On the other hand, intravenous immunoglobulin involves administering a mixture of antibodies to treat a number of health conditions such as myasthenia gravis. Some of the functions of immunoglobulin involve multiple activities such as suppression of idiotypic antibodies, metalloproteinase, and various inflammatory mediators.

Thymectomy accounts as an important constituent for the treatment of myasthenia gravis. With the rising acceptance of minimally invasive thymectomy, the growth of robotic-assisted techniques is on the rise.

Asia Pacific to Emerge as Key Region in Future

The global myasthenia gravis market on the basis of geography has been segmented into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Among them, North America is a key market for myasthenia gravis. According to statistics of Center for Disease Control & Prevention, the prevalence of myasthenia gravis is estimated to be from 14 to 20 per 100,000 population in the United States.

Europe follows North America in terms of revenue contribution to the global myasthenia gravis market. This is mainly because of a growing geriatric population and increasing prevalence of myasthenia gravis.

Asia Pacific, Latin America, and the Middle East and Africa are largely untapped market for myasthenia gravis. Asia Pacific is likely to display leading growth rate among other key regions for myasthenia gravis over the forecast period. Several governmental and non-governmental organizations in the region are involved in organizing awareness programs which is expected to propel the myasthenia gravis market in the region.

Key players in the global myasthenia gravis market include Alexion Pharmaceutical Inc., Avadel Pharmaceuticals plc, CSL Behring, Grifols S.A., Baxter International Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, and Valeant Pharmaceuticals International Inc.

Enquire about this Report @ https://www.mrrse.com/enquiry/4094

About Us

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Matched content

Editor’s pick